@lauralucy72: Camizestrant (Etcamah) with a CDK4/6 inhibitor is now approved in the U.S. for hormone receptor-positive, HER2-negative metastatic breast cancer with an ESR1 mutation. Backed by results from the SERENA-6 trial, which used ctDNA testing to detect emerging ESR1 mutations before cancer progression on a scan. Read more: https://bit.ly/4A2Sz0f #ForYouPage #Stage4Cancer #CancerJourney #breastcancer #CancerJourney

Laura | Stage 4 MBC Remission

Open In TikTok:

Region: GB

Friday 11 September 2026 02:11:41 GMT